Pasar al contenido principal

Miguel Chillon Rodriguez

Dr. M. Chillon has been a senior ICREA researcher since 2001 and Director of the UAB-VHIR Joint Unit since 2017. He obtained his doctorate in Genetics at Hospital Duran i Reynals in 1994. Dr. M. Chillon is Director of the Production Unit of Vectors since 2004, Associate Professor at the UAB since 2005, Principal Investigator of the VHIR since 2017, Co-Chair of the Platform for Advanced Therapies of the European organization EATRIS since 2016, coordinator of the eCORE AVANT of the VHIR since 2022, and scientific advisor of different patient organizations and biotechnological spin-offs

Instituciones de las que forman parte

Jefe de grupo
Terapia Génica en el Sistema Nervioso
Vall Hebron Institut de Recerca

Miguel Chillon Rodriguez

Instituciones de las que forman parte

Jefe de grupo
Terapia Génica en el Sistema Nervioso
Vall Hebron Institut de Recerca

Dr. M. Chillon has been a senior ICREA researcher since 2001 and Director of the UAB-VHIR Joint Unit since 2017. He obtained his doctorate in Genetics at Hospital Duran i Reynals in 1994. Dr. M. Chillon is Director of the Production Unit of Vectors since 2004, Associate Professor at the UAB since 2005, Principal Investigator of the VHIR since 2017, Co-Chair of the Platform for Advanced Therapies of the European organization EATRIS since 2016, coordinator of the eCORE AVANT of the VHIR since 2022, and scientific advisor of different patient organizations and biotechnological spin-offs

Dr. M. Chillon created his research group in 2001 focused from the beginning on four main objectives: (1) gene therapy for cognitive deficits associated with aging; (2) gene therapy for autoimmune diseases; (3) gene therapy for rare diseases that affect the nervous system and (4) development of more efficient gene therapy vectors. Dr. Chillon is the author of 76 scientific articles, 3 reviews, 5 book chapters, editor of 1 book (H index: 27; 3470 citations, Scopus), and has directed 14 doctoral theses (4 in progress) and 22 students of Master. In the last five years, Dr. Chillon has obtained different national and international projects such as the European Joint Program-Rare Diseases AC20/00051; Society Challenges. PID2019-104034RB-I00; Challenges Collaboration RTC2019-006879-1; RICORS of the ISCIII RD21/0017/0008; Santander Foundation (2020); CERVERA IDI-2020-0258; ALS International (2018-0512); SmartMoney-UAB (2017); and Marathon TV3, 201607.10. Regarding technology transfer, Dr. Chillon's group has generated 10 patents and founded 2 spin-off companies: NanoTherapix (2009) for gene and cell therapy for diseases of the immune system; and Klogene (2016) for gene therapy of cognitive impairments. He has also founded the Vector Production Unit (UPV) to value the knowledge generated. Currently, the UPV is the first supplier of Ad and AAV vectors to Spanish groups and has the TECNIO Quality accreditation and ISO9001:2015 accreditation. Finally, in recognition of his career, Dr. M Chillón received the "Transfer Award" in 2018 from the Social Council of the UAB.

Proyectos

ESTUDIO Y DESARROLLO DE LA PRIMERA PLATAFORMA TECNOLÓGICA DE ENSAYOS PARA VIRUS ADENOASOCIADOS EN TERÁPIA GÉNICA

IP: Miguel Chillon Rodriguez
Colaboradores: Susana Miravet Delgado, Laia Rubio Ortega, Marina Tarrés Mercader
Entidad financiadora: Instituto de Salud Carlos III
Financiación: 296571
Referencia: PMPTA22/00048
Duración: 01/01/2023 - 31/12/2024

MECPer-3D - Personalized MECP2 gene therapy using CRISPR/Cas9 technology coupled to AAV-mediated delivery in 3D cell culture and KI mice

IP: Miguel Chillon Rodriguez
Colaboradores: -
Entidad financiadora: Instituto de Salud Carlos III
Financiación:
Referencia: ISCIII/ERA-NET/EJPRD/2020/CHILLON
Duración: -

Terapia génica para MECP2 personalizada utilizando la tecnología CRISPR/Cas9 junto con administración por AAV, en cultivo de células 3D y ratones KI

IP: Miguel Chillon Rodriguez
Colaboradores: -
Entidad financiadora: Instituto de Salud Carlos III
Financiación: 169097.5
Referencia: AC20/00051
Duración: 01/01/2021 - 31/10/2024

Sol·licitud beques Predoctorals. Modalitat VHIR-AGAUR

IP: Miguel Chillon Rodriguez
Colaboradores: Laia Perez Lasarte
Entidad financiadora: Fundació Institut de Recerca HUVH
Financiación: 46800
Referencia: PRED-VHIR-16-34/EDO
Duración: 01/03/2017 - 29/02/2020

Noticias relacionadas

La terapia génica protege, modelos animales, contra los déficits cognitivos asociados al envejecimiento, mejora la función motora y retrasa la aparición de enfermedades como la esclerosis lateral amiotrófica o el Alzheimer.

Durante dos días expertos han presentado los últimos avances en vectores, las diferentes técnicas de modificación de genes y la transferencia a la práctica clínica.

Profesionales sanitarios y de investigación se han reunido para unir sinergias y buscar soluciones innovadoras.

Profesionales relacionados

Raimundo Molina Martínez

Raimundo Molina Martínez

Administrativo/va
Servicios Generales e Infraestructura
Gerencia
Leer más
María Gloria Cereza García

María Gloria Cereza García

Investigador/a principal
Farmacología Clínica
Leer más
Àlex Fonollosa Calduch

Àlex Fonollosa Calduch

Investigador/a principal
Leer más
Francesc Xavier Molero Richard

Francesc Xavier Molero Richard

Investigador/a principal
Fisiología y Fisiopatología Digestiva
Leer más

Suscríbete a nuestros boletines y forma parte de la vida del Campus

Vall d'Hebron Barcelona Hospital Campus es un parque de referencia mundial donde la asistencia, la investigación, la docencia y la innovación se dan la mano.